Using eRapa to prevent bladder cancer recurrence
eRapa for bladder cancer prevention
This study is looking at whether a special version of rapamycin can help prevent bladder cancer from coming back in people who have just been diagnosed with a certain type of bladder cancer, and it will compare this treatment to a placebo over a year to see how well it works and how patients tolerate it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10886777 on NIH RePORTER |
What this research studies
This research investigates the use of an encapsulated formulation of rapamycin (eRapa) to prevent the recurrence of bladder cancer in patients who have been newly diagnosed with non-muscle invasive bladder cancer. The study will involve a phase II double-blind randomized controlled trial comparing eRapa to a placebo over a one-year period. Patients will be monitored for efficacy and tolerance, with the aim of improving immune responses against bladder cancer and enhancing the effectiveness of standard treatments like BCG therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently been diagnosed with non-muscle invasive bladder cancer.
Not a fit: Patients with muscle-invasive bladder cancer or those who have previously undergone extensive bladder cancer treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of bladder cancer recurrence and improve long-term outcomes for patients.
How similar studies have performed: Previous research has shown promising results with mTOR inhibitors in bladder cancer models, suggesting potential for success with this approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Svatek, Robert Scott — University of Texas Hlth Science Center
- Study coordinator: Svatek, Robert Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.